NCT00895271
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Enrolling by Invitation
Not specifiedAges 2–85ObservationalNational Institute of Allergy and Infectious Diseases (NIAID)Government-funded
~200 participants
Updated 2026-08-31 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Generate fibroblast, dermal, or other skin-resident cell lines
Measured over Over the lifetime of the study
Conditions
NCT00895271
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Institutes of Health Clinical Center
Bethesda, Marylandno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Helen C Su, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Generate fibroblast, dermal, or other skin-resident cell linesOver the lifetime of the study
Obtain skin punch biopsies to generate fibroblast, dermal, or other skin-resident cell lines in patients who previously underwent HSCT. Cells may also be used for somatic cell hybridization, cell complementation, assessing fibroblast-specific innate immune responses, or other genetic techniques.